ANI Pharmaceuticals (ANIP) Expected to Post Earnings on Friday

ANI Pharmaceuticals (NASDAQ:ANIP) is expected to be releasing its earnings data before the market opens on Friday, February 28th. Analysts expect ANI Pharmaceuticals to post earnings of $1.41 per share and revenue of $175.36 million for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ:ANIP opened at $59.73 on Friday. ANI Pharmaceuticals has a 12 month low of $52.50 and a 12 month high of $70.81. The firm has a market capitalization of $1.26 billion, a P/E ratio of -108.60 and a beta of 0.74. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. The company’s fifty day moving average price is $57.05 and its 200 day moving average price is $58.24.

Insider Buying and Selling at ANI Pharmaceuticals

In related news, SVP Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $60.00, for a total value of $60,000.00. Following the sale, the senior vice president now directly owns 49,059 shares in the company, valued at $2,943,540. The trade was a 2.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Stephen P. Carey sold 7,500 shares of the business’s stock in a transaction on Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total transaction of $418,425.00. Following the sale, the chief financial officer now owns 154,468 shares in the company, valued at $8,617,769.72. The trade was a 4.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 42,781 shares of company stock worth $2,465,372. 12.70% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several analysts have recently weighed in on ANIP shares. Leerink Partnrs raised ANI Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, December 11th. HC Wainwright reaffirmed a “buy” rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Monday, November 11th. Leerink Partners began coverage on ANI Pharmaceuticals in a report on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 price objective for the company. Finally, StockNews.com raised shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, February 5th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $77.71.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.